Psychological health in patients with amyotrophic lateral sclerosis

Averill, Alyssa J.; Kasarskis, Edward J.; Segerstrom, Suzanne C.

doi:10.1080/17482960701374643

Cited by 89 publications

(51 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reduced physical activity has a negative influence on mental health [33], although data on mood disorders in NMDs are inconsistent. These diseases are often accompanied by psychological distress that in many cases does not satisfy the criteria of clinical depression [2]. Patients with NMDs in our study, as well as those in the study by Kalkman et al [21], had a significantly reduced HRQoL in the SF-36 domains ''mental health'' and ''role limitations due to emotional problems''.…”

Section: Discussionsupporting

confidence: 45%

Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy

et al. 2010

View full text Add to dashboard Cite

Neuromuscular disorders are rare diseases with a chronic and debilitating course. Unfortunately, data on the health-related quality of life (HRQoL) in neuromuscular diseases are limited. The objective of this multicentre cross-sectional study was to compare the HRQoL in patients with amyotrophic lateral sclerosis (ALS), facioscapulohumeral muscular dystrophy (FSHD) and myasthenia gravis (MG) and to identify the determinants of the HRQoL in these diseases. We recruited 91 consecutive outpatients with ALS (n = 37), FSHD (n = 17) or MG (n = 37) in seven specialized German health centres. The HRQoL was determined using the 36-Item Short Form Health Survey (SF-36) and the EuroQol (EQ-5D). Independent predictors of the HRQoL were identified using multiple regression analysis. The HRQoL in all domains of the SF-36, except for bodily pain, was significantly reduced. The domains related to physical health (physical functioning, physical role) were most affected. The EQ-5D-index score was most reduced in ALS (0.54) and least reduced in MG (0.89). Independent predictors of a reduced HRQoL were disease severity and depression in ALS, and disease severity, depression, older age and increased body-mass index in MG. The patterns of HRQoL-impairment in neuromuscular disorders share some common features, such as a more pronounced reduction in the HRQoL related to physical health, but there are a number of disease-specific features that should be considered in outcomes of clinical trials and treatment guidelines. In addition to the treatment of motor symptoms, greater attention should be paid to the treatment of depression, which was found to be among the independent predictors of the HRQoL in ALS and MG.

show abstract

Section: Discussionsupporting

confidence: 45%

Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy

et al. 2010

View full text Add to dashboard Cite

show abstract

“…18 Previous studies rarely examined the temporal pattern of depression prevalence and were mostly based on small numbers of patients (range 27-131). [6][7][8][9][10][11][12][13][19][20][21] A recent meta-analysis identified a total of 3,190 patients with ALS from 103 studies on ALS and depression, 22 whereas in the present study, we were able to enroll 1,752 patients in a single study.…”

Section: Discussionmentioning

confidence: 92%

“…Multiple studies have shown that patients with ALS are more likely to develop depression than ALS-free individuals, although the reported prevalence of depression varies greatly. [6][7][8][9][10][11][12][13] Different measurements of depression together with the varying representativeness of the patient samples used in previous studies may partly explain the different prevalences reported so far.…”

mentioning

confidence: 99%

Depression in amyotrophic lateral sclerosis

et al. 2016

View full text Add to dashboard Cite

Objective: To examine the relative risk of depression among patients with amyotrophic lateral sclerosis (ALS), both in terms of depression diagnosis and use of antidepressant drugs, before and after diagnosis. Methods:We conducted a nested case-control study including 1,752 patients with ALS diagnosed from July 2005 to December 2010 and 8,760 controls based on the Swedish national health and population registers, to assess the associations of depression diagnosis and use of antidepressant drugs with a subsequent risk of ALS. We further followed the patients with ALS after diagnosis to estimate the association of an ALS diagnosis with the subsequent risk of depression and use of antidepressant drugs.Results: Before diagnosis, patients with ALS were at higher risk of receiving a clinical diagnosis of depression compared to controls (odds ratio [OR] 1.7, 95% confidence interval [CI] 1.3-2.3), and the highest risk increase was noted during the year before diagnosis (OR 3.5, 95% CI 2.1-5.6). Patients with ALS also had a highly increased risk of depression within the first year after diagnosis (hazard ratio 7.9, 95% CI 4.4-14.3). Antidepressant use was more common in patients with ALS than in controls, especially during the year before (OR 5.8, 95% CI 4.5-7.5) and the year after (hazard ratio 16.1, 95% CI 11.5-22.6) diagnosis. Approximately 30% of patients with amyotrophic lateral sclerosis (ALS) show mild cognitive impairment and 15% present with overt frontotemporal dementia (FTD). Conclusions:1,2 The overlap between ALS and FTD presents a continuum of symptoms such as memory impairment, apathy, and behavioral changes, 3,4 many of which mimic the typical symptoms of depression. 5The strong emotions evoked by receiving a serious diagnosis such as ALS may also lead to increased risk of mental illnesses, including depression. Multiple studies have shown that patients with ALS are more likely to develop depression than ALS-free individuals, although the reported prevalence of depression varies greatly.6-13 Different measurements of depression together with the varying representativeness of the patient samples used in previous studies may partly explain the different prevalences reported so far.The aim of the present study was to investigate the occurrence of depression diagnosis and use of antidepressants before and after ALS diagnosis in a nationwide sample of patients with ALS, using a matched random sample of the Swedish population as the reference.

show abstract

“…Systematic reviews concluded that major depression is uncommon, affecting between 6 and 12% of patients [12,13]. Recent studies report estimates of 6% for major and 29% for mild depression [14], of 22% for major and minor depression altogether [15].…”

Section: Introductionmentioning

confidence: 99%

“…The assessment of antidepressant medication (ATDs) use was not common practice. Not accounting for the use of ATDs may underestimate depression [12]. When assessed, the prevalence of use ranged from 4 to 38% [7,14,16,17,18,22,23,24].…”

Section: Introductionmentioning

confidence: 99%

The Use of Antidepressant Medication before and after the Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Cohort Study

et al. 2015

View full text Add to dashboard Cite

Background: The prevalent use of antidepressants (ATDs) in patients with Amyotrophic Lateral Sclerosis (ALS) varies across cross-sectional and clinic-based published studies. This population-based cohort study assesses the real-world prevalence of the use of ATDs, its trajectory and the association of incident use with clinical characteristics. Methods: All patients with incident ALS in the Friuli Venezia Giulia region, Italy, from 2002 to 2009, were identified through multiple sources including health databases. Diagnosis was validated through clinical documentation review. ATDs prescriptions from 2000 to 2011 were obtained from regional database. The trajectory was estimated through generalized estimating equations for repeated measures logistic regression and the Hazard ratio (HR) of initiating ATDs through multivariate proportional hazard Cox regression. Results: In this cohort of 261 ALS cases, age-, sex-adjusted prevalence of the use of ATDs was 37.3%, higher than in general population. The trajectory increased by 16% in 1-year period across diagnosis. Age ≤67 years at diagnosis (HR 1.28, 95% CI 0.84-1.95) and bulbar onset (1.43, 95% CI 0.90-2.26) were positively associated with initiating ATDs after diagnosis. Conclusions: More than one-third of patients used ATDs. Depression may occur more frequently than previously reported. Depression may precede motor alterations and be related to both ALS diagnosis and progression.

show abstract

Psychological health in patients with amyotrophic lateral sclerosis

Cited by 89 publications

References 74 publications

Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy

Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy

Depression in amyotrophic lateral sclerosis

The Use of Antidepressant Medication before and after the Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Cohort Study

Contact Info

Product

Resources

About